Skip to main content
Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
5.41
+0.28 (5.46%)
At close: Mar 9, 2026, 4:00 PM EDT
5.45
+0.04 (0.65%)
Pre-market: Mar 10, 2026, 4:23 AM EDT

Iovance Biotherapeutics Revenue

In the year 2025, Iovance Biotherapeutics had annual revenue of $263.50M with 60.60% growth. Iovance Biotherapeutics had revenue of $86.77M in the quarter ending December 31, 2025, with 17.75% growth.

Revenue (ttm)
$263.50M
Revenue Growth
+60.60%
P/S Ratio
8.46
Revenue / Employee
$270,258
Employees
975
Market Cap
2.23B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025263.50M99.43M60.60%
Dec 31, 2024164.07M162.88M13,698.99%
Dec 31, 20231.19M--
Dec 31, 2022---
Dec 31, 2021---
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Galapagos NV 1.31B
Ultragenyx Pharmaceutical 673.00M
Zai Lab 460.16M
Adaptive Biotechnologies 276.98M
Stoke Therapeutics 205.63M
Syndax Pharmaceuticals 172.35M
Day One Biopharmaceuticals 158.18M
Tango Therapeutics 62.38M
Revenue Rankings

IOVA News

More News